

REFERENCES

- Addington J. & Addington D. (1991). Positive and negative symptoms of schizophrenia: their course and relationship over time. *Schizophrenia Research*. 5: 51 - 59.
- Allison D.B. & Mackell J. (2000). Healthcare resource use and body mass index among individuals with schizophrenia. *International Journal of Neuropsychopharmacol*. 3 (Suppl. 1): S124.
- Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., et al. (1999, November). Antipsychotic-induced weight gain: a comprehensive research synthesis. *American Journal of Psychiatry*. 156: 1686-1696.
- Allison D.B., Newcommer J.W., Dunn A.L. (2009). Obesity among those with mental disorders: A National Institute of Mental Health meeting report. *American Journal of Preventive Medicine*. 36: 341-350.
- Alvarez-Jimenez M., Hetrick S.E., Gonzalez-Blanch C., Gleeson J.F., McGorry P.D. (2008). Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. *British Journal of Psychiatry*. 193: 101-107.
- American Experience. (2007). People and Events: Recovery from Schizophrenia. [Online]. Available: http://www.pbs.org/wgbh/amex/nash/peopleevents/e_recovery.html. Accessed. [2007, February 22].
- American Psychiatric Association (2000). "Schizophrenia". *Diagnostic and statistical manual of mental disorders: DSM-IV*. Washington, DC: American Psychiatric Publishing, Inc.. ISBN 0-89042-024-6. [Online].

Available: <http://www.behavenet.com/capsules/disorders/schiz.htm>. Retrieved. [2008, April 7].

Andreasen N.C. & Olsen S. (1982). Negative versus positive schizophrenia: definition and validation. *Archives of General Psychiatry*. 39: 789 - 794.

Andreasen N.C., Paradiso S., O'Leary D.S. (1998). Cognitive dysmetria' as an integrative theory of schizophrenia: a dysfunction in cortical - subcortical - cerebellar circuitry? *Schizophrenia Bulletin*. 24 (2): 203 - 218.

Aramburu C., Drury A., Louis M. (2002, December). Exploring the association between body weight, stigma of obesity, and health care avoidance. 14 (12): 554-561.

Arehart-Treichel J. (2010, August 20). DSM-5 work groups assess thousands of comments . *Psychiatric News* . 45 (16): 14.

Arndt, S., Andreasen, N.C., Flaum, M., Miller, D. Nopoulos, P. (1995). A longitudinal study of symptom dimensions in schizophrenia: prediction and patterns of change. *Archives of General Psychiatry*. 52 (5): 352 - 360.

Aulakh C.S., Hill J.L., Yoney H.T., et al. (1992). Evidence for involvement of 5-HT_{1C} and 5-HT₂ receptors in the food intake suppressant effects of 1-(2, 5-dimethoxy- 4-iodophenyl)-2-aminopropane (DOI). *Psychopharmacologia*. 109: 444-448.

Balentine J. R. & Mathur R. (No date). What is obesity? [Online]. Available: http://www.medicinenet.com/obesity_weight_loss/article.htm. [2010, August 8].

Bandura A. (2008). Sources of Self-Efficacy Beliefs. [Online].

Available: <http://www.addictioninfo.org/articles/2462/1/Self-Efficacy/Page1.html>. [2008, August 26].

- Bandura A. (1993). Perceived self-efficacy in cognitive development and functioning. *Education Psychologist*. 28 (2): 117-148.
- Bandura, A. (1994). Self-efficacy. In V. S. Ramachaudran (Ed.), *Encyclopedia of human behavior* (Vol. 4, pp. 71-81). New York: Academic Press. (Reprinted in H. Friedman [Ed.], *Encyclopedia of mental health*. San Diego: Academic Press, 1998).
- Bandura A. (1991). *Social Foundations of thought and action: a social cognitive Theory*. Englewood Cliffs, NJ: Prentice Hall.
- Baptista T., Hernandez L., Prieto L.A. (2001) Metformin in obesity associated with antipsychotic drug administration: a pilot study. *Journal of Clinical Psychiatry*. 62: 653-655.
- Barness L.A., Opitz J.M., Gilbert-Barness E. (2007, December). "Obesity: genetic, molecular, and environmental aspects". *American Journal of Medicine* 143 (24): 3016–34.
- Barrera A. & Berrios G. E. (2009) Formal Thought Disorder. *Psychopathology* 42: 264-269. Mueser K.T., Jeste D.V. (2008). *Clinical Handbook of Schizophrenia*. New York: Guilford Press. 22–23. ISBN 1593856520.
- Bernstein J.G. (1988). Psychotropic drug induced weight gain: mechanisms and management. *Clinical Neuropharmacology*. 11 (suppl 1): S194-S206.
- Berry S.A. & Mahmoud R.A. (2001, December). Normalization of olanzapine associated abnormalities of insulin resistance and insulin release after switch to risperidone: the risperidone rescue study. Poster presented at the 40th annual meeting of the American College of Neuropsychopharmacology, Kona, HI.

- Bleuler M. (1974). The long -term course of the schizophrenic psychoses. *Psychological Medicine*. 4: 244-254.
- Blog E. (No date). Depression and anxiety: Exercise eases symptoms. [Online]. Available: <http://www.mayoclinic.com/health/depression-and-exercise/MH00043>. [2010, September 8].
- Borrell B. (2007). Using motivational interviewing to promote patient behavior change and enhance health. [Online]. Available. <http://www.esrdnet5.org/5DiamondPtSafety/MissedTreatments/Module%20Package/MT-14.pdf>. [2010, September 8].
- Boyles S. (2006). Obesity increases risks in pregnancy. [Online]. Available: <http://www.webmd.com/diet/news/20060203/obesity-increases-risks-in-pregnancy>. [2010, August 8].
- Bravata D.M., Smith-Spangler C., Sundaram V., et al. (2007) Using pedometers to increase physical activity and improve health. *Journal of the American Medical Association*. 298: 2296-2304.
- Bray G.A. (2004). "Medical consequences of obesity". *Journal of Clinical Endocrinology & Metabolism* . 89 (6): 2583–9.
- Breier A., Schreiber, J. Dyer, J. (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. *Archives of General Psychiatry*. 48: 239 - 246.
- British Columbia Schizophrenia Society. (2006). Basic Facts about Schizophrenia, [Online]. Available : http://www.mentalhealth.com/book/p40-sc02.html#Head_4. Downloaded on. [2009, November 13].
- Brook C. (1977). Genetic aspects of obesity. *Post graduate Med. J.* 53: 93-99.

- Brown S., Inskip H., Barraclough B. (2000) Causes of the excess mortality of schizophrenia. *British Journal of Psychiatry*. 177: 212-217.
- Bumgardner W. (2004). How to walk - arm motion. [Online]. Available : <http://walking.about.com/cs/beginners/a/howarms.htm>. [2010, June 5].
- Bustillo J.R. (2008, June) Schizophrenia. [Online]. Available: <http://www.merck.com/mmpe/sec15/ch202/ch202e.html>. [2008, July 09].
- Butler L. & Dwyer D. (2004) Pedometers may not provide a positive effect on walking activity. *Health Promotion Journal of Australia*.15: 134-136.
- Byerly M.J., Marcus R.N., Quynh-Van T., Eudicone J.M., et al. (2009, February). Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study.
- Cappuccio F. P. (2008). short sleep duration linked to obesity, consistently and worldwide. [Online]. Available: <http://www.sciencedaily.com/releases/2008/05/080501062808.htm>. [2010, July 19].
- Cardno A.G. & Gottesman I.I. (2000). Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. *American Journal of Medical Genetics*. 97 (1): 12-17.
- Cargill B.R., Clark M.M., Pera V., Niaura R.S., Abrams D.B. (1999). Binge eating, body image, depression, and self-efficacy in an obese clinical population. *Obesity Research*. 7: 379-386.
- Casey D. (1996). Seroquel' (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. *Expert Opinion on Investigational Drugs*. 5: 939 – 57.

- Castle D., Wessely S., Der G., Murray R.M. (1991, December). The incidence of operationally defined schizophrenia in Camberwell, 1965-84. *The British Journal of Psychiatry*. 159: 790-4.
- Catapano L. & Castle D. (2004). Obesity in schizophrenia: what can be done about it? *Australas Psychiatry*. 12 (1): 23-5.
- Chan C.B., Spangler E., Valcour J., Tudor-Locke, C. (2003) Cross-section relationship of pedometer-determined ambulatory activity to indicators of health. *Obesity Research*. 11 (12): 1563-1570.
- Ciampi L. (1980) The natural history of schizophrenia in the long term. *British Journal of Psychiatry*. 136: 413-420.
- Citrome L., Blonde L., Damatarca C. (2005) Metabolic Issues in Patients with Severe Mental Illness. *Southern Medical Journal*. 98 (7): 714-719.
- Collis M. (2005). Consulting and clinical psychology: consumption among heavy drinking college students. *Journal of Drug Education*. 25 (61): 455-461.
- Coveli N. H., Weissman E. M., Essock S.M. (2004). Weight gain with clozapine compared to first generation antipsychotic medications. *schizophrenia Bulletin*. 30 (2): 229-240.
- Critchley, E.M.R. (1987). Hallucinations and their impact upon art. Carnegie Press, Preston. *Journal of the History of the Neurosciences: Basic and Clinical Perspectives*. 1 (4): 243 – 267.
- Daley A. J. (2002). Exercise therapy and mental health in clinical populations: is exercise therapy a worthwhile intervention? *Advances in Psychiatric Treatment*. 8: 262-270.

- Davidson S., Judd F., Jolley D., et al. (2001) Cardiovascular risk factors for people with mental illness. *Australian and New Zealand Journal of Psychiatry*. 35: 196-202.
- DeFronzo R.A. & Goodman A.M. (1995) Multicenter Metformin Study Group: efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. *New England Journal of Medicine*. 333: 541-549.
- Dickerson F.B., Brown C.H., Kreyenbuhl J.A., et al., (2006). Obesity among individuals with serious mental illness, *Acta Psychiatrica Scandinavica*. 113. 306–313.
- Dixon L.B., Dickerson F.B., Bellack A.S. et al. (2010). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. *Schizophrenia Bulletin*.36: 48-70.
- Dokken B.B. & Tsu-Shuen T. (No date). The physiology of body weight regulation: are we too efficient for our own good? [Online]. Available: <http://spectrum.diabetesjournals.org/content/20/3/166.full>. [2010, July 5].
- Eder U., Mangweth B., Ebenbichler C. et al. (2001). Association of olanzapine-induced weight gain with an increase in body fat. *American Journal of Psychiatry*. 158: 1719-1722.
- Ehrens K. (No date). Pedometer Pointers. [Online]. Available: <http://www.walknd.com/pedometer.htm>. [2010, July 12].
- Fakhouri W. (1999). Extent of distress caused by adverse experiences associated with antipsychotic treatment. *Journal of the European College of Neuropsychopharmacology*. 9: S285.

Faulkner G., Cohn T., Remington G. (2007). Interventions to reduce weight gain in schizophrenia. *Schizophrenia Bulletin*. 33: 654-656.

Ferdinand R.F., Sondeijker F., Van der E.J., Selten J.P., Huizink A., Verhulst F.C. (2005). "Cannabis use predicts future psychotic symptoms, and vice versa". *Addiction*. 100 (5): 612–618.

Fisher S. (2007). Multiple Intelligences and Mindsets: Positive Approaches to Education. [Online]. Available: [http:// positivepsychologynews.com/news/sherri-fisher/20070405192](http://positivepsychologynews.com/news/sherri-fisher/20070405192). [2010, July 6,].

Fontaine K.R. & Cheskin L.J. (1997) Self-efficacy, attendance, and weight loss in obesity treatment. *Addictive Behaviors*. 22: 567–570.

Fontaine K.R., Heo M., Harrigan E.P., et al. (2001). Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. *Journal of Psychiatric Research*. 101 (3): 277-288.

Fontbonne A., Charles M.A., Juhan-Vague I., et al. (1996). The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. *Diabetes Care*. 19: 920-926.

Foussias G., Mann S., Zakzanis K.K., Reekum R., Remington G. (2009). Motivational deficits as the central link to functioning in schizophrenia: a pilot study. *Schizophrenia Research*. 115:333-337.

Freedman R., Ross R.G., Adler L.E. (No date). Physiological and genetics of schizophrenia [Online]. Available: <http://www.acnp.org/g4/GN401000113/CH111.html/>. [2010, August 27].

- Furst B.A., Champion K.M., Pierre J.M. (2002). Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. *Society of Biological Psychiatry*. 51: 264-265.
- Gallagher D. (2004). Overweight and obesity BMI cut-offs and their relation to metabolic disorders in Koreans/Asians. *Obesity Research* . 12 (3): 440-441.
- Goff D.C., Cather C., Evins A.E., Henderson D.C., Freudenreich O. (2005). Copeland P.M. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists, *Journal of Clinical Psychiatry*. 66: 183–194.
- Goldman H.H. (editor). (1998). *Review of General Psychiatry*, 4th Edition, Appleton and Lange Medical Publications: Norman K. 386.
- Goodall I.E., Oxtoby C., Richards R. (1988). A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. *British Journal of Psychiatry*. 153: 208-213.
- Gorczeni P. & Faulkner G. (2010). Exercise therapy for schizophrenia. *Cochrane Database Systematic Review*.5: CD004412.
- Gorman T. (No date). Power walking techniques that help you lose weight and get in shape. [Online]. Available: <http://ezinearticles.com/?Power-Walking-Techniques-That-Help-You-Lose-Weight-And-Get-In-Shape&id=192477>. [2010, September 7].
- Gortmaker S.L., Must A., Sobol A.M., Peterson K., Colditz G.A., Dietz W.H. (April 1996). "Television viewing as a cause of increasing obesity among children in the United States, 1986–1990". *Arch Pediatr Adolesc Med*. 150 (4): 356–62.
- Gottesman I.I. & Shields J. (1982). *Schizophrenia: The epigenetic puzzle*. New York: Cambridge University Press.

- Graeber D.A., Moyers T.B., Griffith G., Gaujardo E., Tonigan S. (2003). A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. *Community Mental Health*. 39: 189-202.
- Gray J.A. & Roth B.L. (2007, October). "The pipeline and future of drug development in schizophrenia". *Molecular Psychiatry*. 12 (10): 904–22.
- Gregg L., Barrowclough C., Haddock G. (2007). "Reasons for increased substance use in psychosis". *Clinical Psychology Review*. 27 (4): 494–510.
- Groop L. & Orho-Melander M. (2001). The dysmetabolic syndrome. *Journal of Internal Medicine*. 250: 105- 120.
- Guestposter. (No date). How to change an inactive lifestyle into an active one. [Online]. Available: <http://www.loseadoublechin.com/how-to-change-an-inactive-lifestyle-into-an-active-one/> [2010, January 23].
- Guy W., editor. (1979). ECDEU Assessment manual for psychopharmacology. 125-126.
- Gwinup G. (1987). "Weight loss without dietary restriction: Efficacy of different forms of aerobic exercise". *American Journal of Sports Medicine*. 15 (3): 275–9.
- Harris E. & Barraclough B. (1998). Barraclough B. Excess mortality of mental disorder. *British Journal of Psychiatry*. 173: 11-53.
- Harrison P.J. & Owen M.J. (2003). "Genes for schizophrenia? Recent findings and their pathophysiological implications". *The Lancet*. 361 (9355): 417–19.
- Haskell W.L., Lee I.M., Pate R.R. (2007, August). "Physical activity and public health: updated recommendation for adults from the American College of

Sports Medicine and the American Heart Association". *Circulation*. 116 (9): 1081–93.

Haslam D.W. & James W.P. (2005). "Obesity". *The Lancet* 366 (9492): 1197–1209.

Heckert P.A. (2007, Jun 4). The Caloric Requirements of Daily Walking for Health and Fitness. [Online]. Available: <http://www.suite101.com/content/10000-steps-to-healthy-weight-loss-a22829>. [2009, June 9].

Hemmingsson E. (2005). Prognosis in obesity; Obstacles must be removed to prevent obesity through increased physical activity. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188144/>. [2010, August 20].

Herring R. (No date). Race walking. [Online]. Available: <http://www.bodybuilding.com/fun/randy34.htm>. [2010, August 28].

Hill J.O. & Wyatt H.R. (2005). Pedometers are perceived as useful tools for weight loss. *Journal of Extension*. April. 2009 47 (2): 1-5.

Hirsch J. (No date). Pathophysiology of obesity. [Online]. Available: <http://jn.nutrition.org/cgi/content/full/127/9/1874S#FN1>. [2010, August 28].

Howard N.J., Taylor A., Gill T., Chittleborough C. (2008, March). "Severe obesity: Investigating the socio-demographics within the extremes of body mass index". *Obesity Research & Clinical Practice*. 2 (1): 51–59.

Huang M-C., Lu M-L., Tsai C-J. (2009). Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. *Acta Psychiatrica Scandinavica*. 120: 274-280.

- Jakobsen K.D. (2005). Reliability of clinical ICD-10 schizophrenia diagnoses. *Nordic Journal of Psychiatry*. 59 (3): 209–12.
- Johansson E., Bockerman P., Kiiskinen U., Heliövaara M. (2009). "Obesity and labour market success in Finland: The difference between having a high BMI and being fat." *Economics and Human Biology*. 7 (1): 36–45.
- Johnson A.A. (No date) Fitness, health and weight loss one step at a time. [Online]. Available: <http://www.chooseenergy.ca/blog/?p=72>. [2010, July 27].
- Jones H.M. & Pilowsky L.S. (2002). "Dopamine and antipsychotic drug action revisited". *British Journal of Psychiatry*. 181: 271–275.
- Jones R. (No date). How to stick with exercise. [Online]. Available: [http://www.ronjones.org/Handouts/SelfEfficacy& Exercise.pdf](http://www.ronjones.org/Handouts/SelfEfficacy&Exercise.pdf). [2010, April 5].
- Kareem F.A. (No date). Obesity. [Online]. Available: <http://apnamalegaon.com/2009/07/obesity/>. [2010, August 29].
- Kawachi I. (1999). Physical and psychological consequences of weight gain. *Journal of Clinical Psychology*. 60 (suppl 21): 5–9.
- Kety S.S., Rosenthal D., Wender P.H., (1968) Schulsinger, F. The types and prevalence of mental illness in the biological and adoptive families of adopted people with schizophrenia. In D. Rosenthal and S.S. Kety (eds.), *The Transmission of Schizophrenia*, New York: Pergamon Press.
- Kingsbury S.J., Fayek M., Trufasiu D. (2001). The apparent effects of ziprasidone on plasma lipids and glucose. *Journal of Clinical Psychology*. 62: 347-349.
- Knight A. (1985). Astemizole: a new, non-sedating antihistamine for hay fever. *Journal of Otolaryngology*. 14: 85-88.

- Kolokowska T., Gadhvi H., Molyneux S. (1987). An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. *International Clinical Psychopharmacology*. 2: 83-88.
- Kolotkin R.L., Corey-Lisle P.K., Crosby R.D. (2008). Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. *Obesity (Silver Spring)*.16: 749-754.
- Kolotkin R.L., Crosby R. D., Williams G.R, Hartley G.G., Nicol S. (2001). The relationship between health-related quality of life and weight loss. *Obesity Research* 9: 564–571.
- Kraepelin E. (1999). *Dementia praecox and paraphrenia* . Edinburgh, E&S Livingstone.
- Krall E.A. & Dawson-Hughes B. (1994, January). Walking is related to bone density and rates of bone loss. *American Journal of Medicine* . 96 (1): 20-6.
- Kraus T., Haack M., Schuld A. (1999). Body weight and leptin plasma levels during treatment with antipsychotic drugs. *American Journal of Psychiatry*. 156: 312-314.
- Kumra S., Shaw M., Merka P., Nakayama E., Augustin R. (2001). "Childhood-onset schizophrenia: research update". *Canadian Journal of Psychiatry*. 46 (10): 923–930.
- Layton J. (2010). Is a lack of sleep making me fat? [Online]. Available: <http://health.howstuffworks.com/mental-health/sleep/basics/sleep-obesity.htm>. [2010, April 20].
- Lean M.E.J. (2000, August). Pathophysiology of obesity. *Proceedings of The Nutrition Society*. 59 (3):331-336.

- Lean M.E.J. (June 2005). Prognosis in obesity: We all need to move a little more, eat a little less. *British Medical Journal*. 330 (7504): 1339–1340.
- Levine S.Z., Rabinowitz J., Engel al., Etschel E., Leucht S. (2008, January) Extrapolation between measures of symptom severity and chang: an examination of the PANSS and CGI. *Schizophrenia Research*. 98 (1-3): 318-322.
- Li L. & Renier G. (2007). Adipocyte-derived Lipoprotein Lipase Induces Macrophage Activation and Monocyte Adhesion: Role of Fatty Acids. *Obesity*. 15: 2595–2604.
- Lieberman J.A., Stroup T.S., McEvoy J.P., et al. (2005, September). "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia". *New England Journal of Medicine*. 353 (12): 1209–23.
- Luis S. R. (2009). Holistic living - build self efficacy. [Online]. Available: http://www.lifepositive.com/Mind/Personal_Growth/Build_Self_Efficacy42008.asp#top. [2010, April 14].
- Maglione M. & Tu W. (2005, April). "Meta-analysis: pharmacologic treatment of obesity". *Annals of Internal Medicine*. 142 (7): 532–46.
- Martin T. (2008). smoking and metabolism. [Online]. Available: <http://quitsmoking.about.com/od/weightgain/a/metabolism.htm>. [2010, April 12].
- McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R M. (2007, July). Efficacy and Tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. *American Journal of Psychiatry*. 164: 1050-1060.

- McFarlane W.R., Dixon L., Lukens E., Lucksted A. (2003, April). "Family psychoeducation and schizophrenia: a review of the literature". *Journal of Marital and Family Therapy*. 29 (2): 223–45.
- Meats P. (1997). Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic. *Journal of Psychiatry in Clinical Practice*. 1: 231 – 239.
- Melamed Y., Stein-Reisner O., Gelkopf M., Levi et al. (2008). A Multi-modal weight control intervention for people with persistent mental disorders. *Journal of Psychiatric Rehabilitation*. 31: 194-200.
- Meyer J.M. (2002). A retrospective comparison of lipid, glucose and weight changes at one year between olanzapine and risperidone treated inpatients. *Journal of Clinical Psychiatry* . 63: 425-433.
- Meyer J.M. (2001). Novel antipsychotics and severe hyperlipidemia. *Journal of Clinical Psychopharmacology*. 21: 369-374.
- Miller W. R. (1983). Motivational interviewing: III. On the ethics of motivational intervention. *Behavioural & Cognitive Psychotherapy*. 22: 111-123.
- Miller W. R. & rollnicks S. (Eds) (1991). *Motivational interviewing: preparing people to change addictive behaviour*. New York: Guilford Press.
- Miller W. R., Zweben A., DiClemente C., Rychtarik, R. G. (1992). *Motivational Enhancement Therapy manual: a clinical research guide for therapists treating change*. *British Medical Journal*. 307: 188-190.
- Moore B.E. & Fine B.D. (1968). A glossary of psychoanalytic terms and concepts, *Journal of the American Psychoanalytic Association*. 78.

- Morrison J.A., Cottingham E.M., Barton B.A. (2002) Metformin for weight loss in pediatric patients taking psychotropic drugs. *American Journal of Psychiatry*. 159: 655-657.
- Mueser K.T. and McGurk S.R. (2004, January). *Schizophrenia*. *Lancet*. 19; 363 (9426): 2063-2072.
- Murphy B.P. (2006, December). "Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review". *Schizophrenia Research*. 88 (1-3): 5–25.
- Murphy M.H. & Hardman A..E. (1998, January). Training effects of short and long bouts of brisk walking in sedentary women. *Medicine & Science in Sports & Exercise* .30 (1): 152-157.
- Musto A.A. (2008). "The effect of an incremental pedometer program on metabolic syndrome components in sedentary overweight women". PhD. Thesis University of Miami.
- Mwape C. (No date). The amazing health benefits of walking for exercise. [Online]. Available: <http://www.changingshape.com/resources/articles/benefits-of-exercise.asp>. [2010, August 31].
- Ness-Abramof R. & Apovian C.M. (2006, February). "Diet modification for treatment and prevention of obesity". *Endocrine*. 29 (1): 5–9.
- Newman S.C. & Bland R.C. (1991). Mortality in a cohort of patients with schizophrenia: a record linkage study. *Canadian Journal of Psychiatry*. 36: 239–245.
- O'Donohue W. (2003). Psychological skills training: issues and controversies. *Behavior Analyst Today*. 4 (3): 331- 335.

- O'Donohue W. & Krasner L. (1995). Psychological skills training. In W. O'Donohue W. & L. Krasner (Eds.), *Handbook of psychological skills training: Clinical techniques and applications*. Boston: Allyn and Bacon. 1-19.
- Ornes L.L., Ransdell L.B., Robertson L., Trunnell E., Moyer-Mileur L. (2005). A 6-month pilot study of effects of a physical activity intervention on life satisfaction with a sample of three generations of women. *Perceptual and motor skills*. 100 (3 pt 1): 579-591.
- Pal S., Cheng C., Egger G., Binns C., Donovan R. (2009). Using pedometers to increase physical activity in overweight and obese women: a pilot study. *BMC Public Health*. 9 (309): 1-9.
- Peeke P. (No date). Expert Q&A: Fighting midlife weight gain [Online]. Available: <http://www.webmd.com/diet/guide/expert-qa-fighting-midlife-weight-gain-pamela-peeke>. [2010, February 2].
- Perkins D.O. (2002, December 12). Predictors of noncompliance in patients with schizophrenia. *Journal of Clinical Psychiatry*. 63: 1121-1128.
- Perkins D.O. (1999) Adherence to antipsychotic medication. *Journal of Clinical Psychiatry*. 60 (Suppl. 21): 25–30.
- Perry C.K., Rosenfeld A.G., Bennett J.A. (2007, July-August). Potempa K. Heart-to-Heart: promoting walking in rural women through motivational interviewing and group support. *Journal of Cardiovascular Nursing*. 22 (4): 304-12.
- Pi-Sunyer F.X. (2006). Use of Lifestyle Changes Treatment Plans and Drug Therapy in Controlling Cardiovascular and Metabolic Risk Factors. *Obesity*. 14: 135S–142S.

- Prochaska J.O., Norcross J.C., Fowler J.L., Follick M.J., Abrams D.B. (1992). Attendance and outcome in a work site weight control program: processes and stages of change as process and predictor variables. *Addictive Behaviors*. 17: 35–45.
- Researcher's toolkit. (2009). "Two samples using average values". [Online]. Available: http://www.dssresearch.com/toolkit/sscalc/size_a2.asp. [2009, November 2].
- Richard W. (1995). Trends in Schizophrenia: Changes in Obstetric Risk Factors with Industrialization. *Schizophrenia Bulletin*, National Institute of Mental Health. 21 (3).
- Richardson C.R., Newton T.L., Abraham J.J., Sen A., Jimbo M., Sartz A.M. A. (2008). meta-analysis of pedometer-based walking interventions and weight loss. *Annals Journal Club*. 6 (1): 69-77.
- Risen T., Bosaeus I., Tölli J., Lindstedt G., Bengtsson B.A. (1993). "Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency". *Clinical Endocrinology*. 38 (1): 63–71.
- Rockwell W.J., Ellinwood E.H., Trader D.W. (1983). Psychotropic drugs promoting weight gain: health risks and treatment implications. *Southern Medical Journal*. 76: 1407-1412.
- Roizen M F. (2010). Ten easy steps to a healthier heart. [Online]. Available: <http://www.rd.com/living-healthy/10-easy-steps-to-prevent-coronary-heart-disease/article32996.html>. [2010, June 15].
- Rollnick S. & Mille W.R. (1995) What is MI? [Online]. Available: <http://www.motivationalinterview.org/clinical/whatismi.html> . [2010, April 13].

- Rooney B., Smalley K., Larson J., Havens S. (2003). Pedometers Are Perceived as Useful Tools for Weight Loss. *American Journal of Medicine*. 123 (1): 111-121.
- Saarni S.E., Saarni S.I., Fogelholm M. (2009). Body composition in psychotic disorders: a general population survey. *Psychological Medicine*. 39: 801-810.
- Saatci E., Tahmiscioglu G., Bozdemir N., Akpinar E., Ozcan S., Kurdak H. (2010). The well-being and treatment satisfaction of diabetic patients in primary care. *Health and Quality of Life Outcomes*. 8:67.
- Sachs G.S. & Guille C. (1999). Weight gain associated with use of psychotic medications. *Journal of Clinical Psychiatry*. 60: 16–19.
- Saffold F. (2005). Increasing self-efficacy through mentoring. *Academic Exchange Quarterly*. 9 (4): 1446-1453.
- Samanin R. & Garattini S. (1990). The pharmacology of serotonergic drugs affecting appetite, in *Nutrition and the Brain*, Vol 8. Edited by Wurtman R,J., Wurtman J.J. New York, Raven. 163-192.
- Schlosser E. (2001). *Fast food nation: the dark side of the all-American meal*. Boston, Houghton Mifflin Harcourt.
- Schotte A., Janssen P.F., Megens A.A. (1993). Occupancy of central neurotransmitter receptors by risperidone, clozapine, and haloperidol measured ex vivo by quantitative autoradiography. *Brain Research*. 631: 191-202.
- Schunk D. H. (1989). Self-efficacy and cognitive skill learning. In C. Ames & R. Ames (Eds.), *Research on motivation in education*. Vol. 3: Goals and cognitions. San Diego: Academic Press. 13-44.

Schwarzer R., & Rrenner B. (No date). Health-specific self-efficacy scales. [Online]. Available [http://www. RalfSchwarzer.ed /](http://www.RalfSchwarzer.ed/). [2008, November 2].

Selten J.P., Cantor-Graae E., Kahn R.S. (2007, March). "Migration and schizophrenia". *Current Opinion in Psychiatry*. 20 (2): 111–115.

Shai L., Schwarzfuchs D., Henkin Y., Shahar D.R., et al. (2008). Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet. *New England Journal of Medicine*. 359: 229-241.

Shick S.M., Wing R.R., Klem M.L., McGuire M.T., Hill J.O., Seagle H. (1998, April). "Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet". *Journal of the American Dietetic Association*. 98 (4): 408–13.

Shirley A.J. (2010). Walking site.[Online]. Available: <http://www.bellaonline.com/subjects/3780.asp>. [2010, July 20].

Silverstone T., Smith G., Goodall E. (1988). Prevalence of obesity in patients receiving depot antipsychotics. *Br J Psychiatry*. 153: 214-217.

Sims A. (2002). *Symptoms in the mind: an introduction to descriptive psychopathology*. Philadelphia: W. B. Saunders. ISBN 0-7020-2627-1.

Snehalatha C., Viswanathan V., Ramachandran A. (2003, May). Cutoff values for normal anthropometric variables in Asian Indian adults. *Diabetes Care*. 26 (5): 1380-1384.


Sperling L.S. (2009). Why being apple-shaped puts your heart at risk. [Online]. Available: <http://www.health.com/health/condition-video/0,,20193389,00.html>. [2009, August 9].

- Taylor J. A. (2009). Walking technique and form. [Online]. Available: http://www.walkingconnection.com/Walking_Technique_Form.html. [2009, February 7].
- Tecott L., Sun L., Arkana S. (1995). Eating disorder and epilepsy in mice lacking 5-HT_{2C} serotonin receptors. *Nature*. 374: 542-546.
- Teixeira P.J., Going S.B., Houtkooper L.B., et al. (2004). Pretreatment predictors of attrition and successful weight management in women. *International Journal of Obesity and Related Metabolic Disorder*. 28: 1124-1133.
- Thakore J.H. (2004). Metabolic disturbance in first-episode schizophrenia. *British Journal of Psychiatry*. 184: S76-S79.
- Thakore J.H. & Leonard B.E. (eds). (2009). *Metabolic effects of psychotropic drugs. Mod Trends Pharmacopsychiatry*. Basel, Karger. 26: 25–46.
- Tice J.A., Karliner L., Walsh J., Petersen A.J., Feldman M.D. (2008, October). "Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures". *American Journal of Medicine*. 121 (10): 885–893.
- Velligan D.I. & Alphas L.D. (2008, March 1). "Negative Symptoms in Schizophrenia: The Importance of Identification and Treatment". *Psychiatric Times*. 25 (3).
- Venuto T. (No date). The 2 pounds per week rule and how to burn fat faster. [Online]. Available: http://www.burnthefatblog.com/archives/2009/02/the_2_pounds_per_week_rule_and.php2/8/. [2010, June 9].
- Vita A. & De P.L. (2007, August). "The effects of antipsychotic treatment on cerebral structure and function in schizophrenia". *International Review of Psychiatry*. 19 (4): 429–36.

- Wahner P. (2007). Getting a Good Workout with Low Impact Exercise. [Online]. Available: <http://exercise.about.com/od/cardioworkouts/a/lowimpact.htm>. [2010, August 12].
- Wahlbeck K., Cheine M.V., Essali A. (2007). "Clozapine versus typical neuroleptic medication for schizophrenia". The Cochrane Database of Systematic Reviews (John Wiley and Sons, Ltd.).
- Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., et al. (2008, April) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science*. 25; 320 (5875): 539-543.
- Weiden P.J., Simpson D.G., Romano S.J. (2003, December). Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone. *Journal of Clinical Psychopharmacology*. 23 (6): 595-600.
- Weiden P.J., Allison D.B., Mackell J.A., (2000, May). Obesity as a risk factor for antipsychotic noncompliance. Poster presented at the annual meeting of the American Psychiatric Association, Chicago, IL.
- Weiden P.J., Mackell J.A., McDonnell D.D. (2001). Obesity as a risk factor for antipsychotic noncompliance. *J Eur Coll Neuropsychopharmacol*. 10(Suppl. 3): S289.
- Werneke U., Taylor D., Sanders T.A. (2002). Options for pharmacological treatment of obesity in patients treated with atypical antipsychotics. *International Clinical Psychopharmacology*. 17: 145-160.
- Wirshing D.A., Boyd J., Meng L., et al. (2001) Antipsychotic medication: impact on coronary artery disease risk factors. *Society of Biological Psychiatry*. 49: 175S.

- Wirshing D.A. & Meyer J.M. (2009, January 9). Weight Monitoring for Schizophrenia. . [Online]. Available: <http://www.health.am/psy/more/weight-monitoring-for-schizophrenia/>. [2009, August 9].
- Wirshing D.A., Wirshing W., Kysar L. (1999). Novel antipsychotics: comparison of weight gain liabilities. *Journal of Clinical Psychiatry*. 60: 358-363.
- Wolff GL. (1997, September). Overview. *The Journal of Nutrition*. 127 (9): 1871S-1873S.
- Wongchaisuwan T., Sithinamsuwan P., Udommongkol C., Wongmek W. (2005). Factors influencing MMSE-T score among Thai subjects. *Journal of The Medical Association of Thailand* . 88 (Suppl 3): S155-8.
- World Health Organization. (2004). *World Health Organization Quality of Life (WHOQOL)-BREF*. World Health Organization: Geneva.
- Wykes T., Steel C., Everitt B., Tarrier N. (2008, May). "Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor". *Schizophrenia Bull*. 34 (3): 523–37.
- Yaffe K., Barnes D, Nevitt M., Li-Yung L., Covinsky K. (2001, July 23). Prospective study of physical activity and cognitive decline in elderly women. *Archives of Internal Medicine*. 161: 1073-1078.
- Yao G., Chung C.W., Yu C.F., Wang J.D. (2002, May). Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. *Journal of the Formosan Medical Association*. 101(5):342-51.

Zheng H., Lenard N.R., Shin A.C. Berthoud H-R. (2009) Appetite control and energy balance regulation in the modern world: reward-driven brain overrides repletion signals. *International Journal of Obesity*. 33: S8–S13.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved